CDE Releases 58th and 59th Batches of Chemical Generic Reference Preparations
The Center for Drug Evaluation (CDE) has released the 58th and 59th batches of chemical...
Shenzhen’s LWPOCT Secures RMB 100 Million in Series A Round for CDMO Expansion
Shenzhen-based medical devices and reagents manufacturer Shenzhen Living Water POCT Co., LTd (LWPOCT) has reportedly...
Henlius Biotech Begins Global Phase III Trial for Denosumab Biosimilar HLX14
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...
Cellular Biomedicine Group’s C-CAR039 Receives NMPA Approval for B-Cell NHL Study
China-based Cellular Biomedicine Group Inc. (CBMG), a private company following a merger deal in February...
Global Cord Blood Corp’s Cellenkos Gets FDA Nod for Myelofibrosis Trial
Global Cord Blood Corporation (GCBC; NYSE: CO) announced receiving Investigational New Drug (IND) approval from...
Hangzhou Tongee Medical Closes RMB 100 Million Series B Round for Gastric Bypass Stent
Hangzhou Tongee Medical Technology Co., Ltd, a Chinese device maker specializing in metabolic disease treatments,...
Scotland Reports First Case of ASHep-UA in Children, WHO Issues Guidelines
Scotland recorded its first case of acute severe hepatitis of unknown etiology in children (ASHep-UA)...
Walvax’s mRNA Vaccine AWcorna Shows Superior Immune Response in Phase III Trial
Walvax Biotechnology Co., Ltd’s (SHE: 300142) mRNA vaccine against SARS-CoV-2, named AWcorna, has reached the...
Tianhe-2 Supercomputer Aids Drug Discovery with Deep-Learning Biosynthetic Tool
China’s Tianhe-2 supercomputer, ranked among the top-10 fastest computers globally, has demonstrated potential in enhancing...
Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China
China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) announced a licensing agreement with compatriot...
Sichuan Meida’s Phentolamine Gains Priority Review for Pheochromocytoma Treatment
The Center for Drug Evaluation (CDE) website indicates that Sichuan Meida Kangjiale Pharmaceutical Co., Ltd’s...
Mabwell’s 6MW3511 Accepted by NMPA for Advanced Solid Tumor Treatment
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that a clinical trial filing for...
NMPA Approves 164 Medical Devices in May 2022, Including Medtronic and Boston Scientific Products
The National Medical Products Administration (NMPA) approved a total of 164 medical devices for marketing...
Boao Lecheng Sees Surge in Drug Use and Medical Tourism Amid Global Partnerships
The Boao Lecheng Medical Tourism Pilot Zone reported a significant increase in special drug and...
Takeda’s Obizur Accepted by China’s NMPA for Acquired Hemophilia A Treatment
Takeda Pharmaceutical Co., Ltd’s (NYSE: TAK, TYO: 4502) China unit announced that a New Drug...
Sirnaomics’ STP705 Shows Promising Results in Skin Cancer Trial
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the peer-reviewed publication of Phase IIa...
Joincare Pharmaceutical Plans USD 300-400 Million GDR Issue for Global Expansion
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced plans to issue Global Depository...
HitGen Inc. Forms Strategic Partnership for New Drug Research and Development
China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...
Yabao Pharmaceutical’s YBSW015 Gets Australian Ethical Approval for COVID-19 Trial
China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received clinical...
Suzhou Zelgen’s JAK Inhibitor Jacktinib Gets NMPA Green Light for COVID-19 Trial
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received approval...